Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
Nka AD, Bouba Y, Teto G, Semengue ENJ, Takou DK, Ngueko AMK, Fabeni L, Carioti L, Armenia D, Pabo W, Dambaya B, Sosso SM, Colizzi V, Perno CF, Ceccherini-Silberstein F, Santoro MM, Fokam J, Ndjolo A. Nka AD, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):272-275. doi: 10.1093/jac/dkac388. J Antimicrob Chemother. 2022. PMID: 36411257
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Gianotti N, et al. J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. J Antimicrob Chemother. 2019. PMID: 31173639
Evaluation of archived drug resistance mutations in HIV-1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID-19 pandemic.
Ka'e AC, Fokam J, Togna Pabo WLR, Nanfack A, Ngoufack Jagni Semengue E, Bouba Y, Nka AD, Tetang S, Beloumou G, Takou D, Chenwi C, Tommo Tchouaket MC, Abba A, Djupsa S, Sosso SM, Pamen NB, Otshudiema JO, Boum Y 3rd, Colizzi V, Ndjolo A, Perno CF, Ceccherini-Silberstein F, Santoro MM. Ka'e AC, et al. HIV Med. 2023 Jun;24(6):691-702. doi: 10.1111/hiv.13459. Epub 2023 Jan 30. HIV Med. 2023. PMID: 36717222
Inflammatory profile of vertically HIV-1 infected adolescents receiving ART in Cameroon: a contribution toward optimal pediatric HIV control strategies.
Ka'e AC, Nanfack AJ, Ambada G, Santoro MM, Takou D, Semengue ENJ, Nka AD, Bala MLM, Endougou ON, Elong E, Beloumou G, Djupsa S, Gouissi DH, Fainguem N, Tchouaket MCT, Sosso SM, Kesseng D, Ndongo FA, Sonela N, Kamta ACL, Tchidjou HK, Ndomgue T, Ndiang STM, Nlend AEN, Nkenfou CN, Montesano C, Halle-Ekane GE, Cappelli G, Tiemessen CT, Colizzi V, Ceccherini-Silberstein F, Perno CF, Fokam J. Ka'e AC, et al. Front Immunol. 2023 Aug 14;14:1239877. doi: 10.3389/fimmu.2023.1239877. eCollection 2023. Front Immunol. 2023. PMID: 37646023 Free PMC article.
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.
Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani". Zaccarelli M, et al. Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9. Infection. 2009. PMID: 19274429
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Mussini C, et al. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. PLoS One. 2015. PMID: 26640953 Free PMC article.
324 results